Summary

The global Anti-GFP Antibody market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Anti-GFP Antibody refers to an antibody that specifically recognizes and binds to green fluorescent protein (GFP). GFP is a naturally occurring protein that emits green fluorescence when exposed to light in the blue to UV range. It is widely used as a reporter molecule in molecular biology and cell biology research to visualize protein expression and localization in vivo. The Anti-GFP Antibody is used to detect and quantify GFP-tagged proteins in various experimental settings, including western blotting, immunofluorescence, and immunohistochemistry.
The industry trend for Anti-GFP Antibody has experienced significant growth due to the increasing use of GFP in genetic engineering, cell tracking, and fluorescence microscopy. The antibody is essential for researchers to validate the successful expression and functionality of GFP-tagged fusion proteins in their experimental systems. Furthermore, the development of more sensitive and specific Anti-GFP Antibodies, as well as the expansion of applications such as live-cell imaging and protein-protein interaction studies, is driving the demand for this product. As the field of fluorescent protein technology continues to advance, the industry trend for Anti-GFP Antibody is expected to remain strong.
The global Anti-GFP Antibody market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.
Market Segmentation
By Company:
FUJIFILM Wako Chemicals
ProSci
GeneTex
Bioss
Rockland Immunochemicals
Cell Signaling Technology
Novus Biologicals
Thermo Fisher Scientific
Biorbyt
R&D Systems
BioLegend
OriGene Technologies
ImmuQuest
Abbexa
EpiGentek
Synaptic Systems
Santa Cruz Biotechnology
Proteintech Group
IBL
LSBio
Signalway Antibody
Agrisera
Bio X Cell
StressMarq Biosciences
RayBiotech
Abnova
Segment by Type
Monoclonal Antibody
Polyclonal Antibody
Segment by Application
Biotechnology
Medical
University
Others
By Region
Macro-Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Markets
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
(Additional regions can be customized based on client needs.)
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term)
Chapter 2: Quantitative analysis of Anti-GFP Antibody market size and growth potential at global, regional, and country levels
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus)
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities
Chapter 6: Regional revenue breakdown by company, type, application and customer
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Anti-GFP Antibody value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032
1.2.2 Monoclonal Antibody
1.2.3 Polyclonal Antibody
1.3 Market by Application
1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032
1.3.2 Biotechnology
1.3.3 Medical
1.3.4 University
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-GFP Antibody Market Perspective (2021-2032)
2.2 Global Market Size by Region: 2021 vs 2025 vs 2032
2.3 Global Anti-GFP Antibody Market Share by Revenue, by Region (2021-2026)
2.4 Global Anti-GFP Antibody Revenue Forecast by Region (2027-2032)
2.5 Major Regions and Emerging Markets Analysis
2.5.1 North America Anti-GFP Antibody Market Size and Prospective (2021-2032)
2.5.2 Europe Anti-GFP Antibody Market Size and Prospective (2021-2032)
2.5.3 Asia-Pacific Anti-GFP Antibody Market Size and Prospective (2021-2032)
2.5.4 Latin America Anti-GFP Antibody Market Size and Prospective (2021-2032)
2.5.5 Middle East & Africa Anti-GFP Antibody Market Size and Prospective (2021-2032)
3 Breakdown Data by Type
3.1 Global Anti-GFP Antibody Historical Market Size by Type (2021-2026)
3.2 Global Anti-GFP Antibody Forecasted Market Size by Type (2027-2032)
3.3 Representative Players for Different Types of Anti-GFP Antibody
4 Breakdown Data by Application
4.1 Global Anti-GFP Antibody Historical Market Size by Application (2021-2026)
4.2 Global Anti-GFP Antibody Forecasted Market Size by Application (2027-2032)
4.3 New Sources of Growth in Anti-GFP Antibody Applications
5 Competitive Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Anti-GFP Antibody Players by Revenue (2021-2026)
5.1.2 Global Anti-GFP Antibody Market Share by Revenue, by Players (2021-2026)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Anti-GFP Antibody Revenue
5.4 Global Anti-GFP Antibody Market Concentration Analysis
5.4.1 Global Anti-GFP Antibody Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Anti-GFP Antibody Revenue in 2025
5.5 Global Key Players of Anti-GFP Antibody Head Offices and Areas Served
5.6 Global Key Players of Anti-GFP Antibody, Product and Application
5.7 Global Key Players of Anti-GFP Antibody, Date of Entry into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Anti-GFP Antibody Revenue by Company (2021-2026)
6.1.2 North America Market Size by Type
6.1.2.1 North America Anti-GFP Antibody Market Size by Type (2021-2026)
6.1.2.2 North America Anti-GFP Antibody Market Share by Type (2021-2026)
6.1.3 North America Market Size by Application
6.1.3.1 North America Anti-GFP Antibody Market Size by Application (2021-2026)
6.1.3.2 North America Anti-GFP Antibody Market Share by Application (2021-2026)
6.1.4 North America Anti-GFP Antibody Major Customers
6.1.5 North America Market Trends and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Anti-GFP Antibody Revenue by Company (2021-2026)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Anti-GFP Antibody Market Size by Type (2021-2026)
6.2.2.2 Europe Anti-GFP Antibody Market Share by Type (2021-2026)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Anti-GFP Antibody Market Size by Application (2021-2026)
6.2.3.2 Europe Anti-GFP Antibody Market Share by Application (2021-2026)
6.2.4 Europe Anti-GFP Antibody Major Customers
6.2.5 Europe Market Trends and Opportunities
6.3 Asia-Pacific Market: Players, Segments, Downstream and Major Customers
6.3.1 Asia-Pacific Anti-GFP Antibody Revenue by Company (2021-2026)
6.3.2 Asia-Pacific Market Size by Type
6.3.2.1 Asia-Pacific Anti-GFP Antibody Market Size by Type (2021-2026)
6.3.2.2 Asia-Pacific Anti-GFP Antibody Market Share by Type (2021-2026)
6.3.3 Asia-Pacific Market Size by Application
6.3.3.1 Asia-Pacific Anti-GFP Antibody Market Size by Application (2021-2026)
6.3.3.2 Asia-Pacific Anti-GFP Antibody Market Share by Application (2021-2026)
6.3.4 Asia-Pacific Anti-GFP Antibody Major Customers
6.3.5 Asia-Pacific Market Trends and Opportunities
6.4 Latin America Market: Players, Segments, Downstream and Major Customers
6.4.1 Latin America Anti-GFP Antibody Revenue by Company (2021-2026)
6.4.2 Latin America Market Size by Type
6.4.2.1 Latin America Anti-GFP Antibody Market Size by Type (2021-2026)
6.4.2.2 Latin America Anti-GFP Antibody Market Share by Type (2021-2026)
6.4.3 Latin America Market Size by Application
6.4.3.1 Latin America Anti-GFP Antibody Market Size by Application (2021-2026)
6.4.3.2 Latin America Anti-GFP Antibody Market Share by Application (2021-2026)
6.4.4 Latin America Anti-GFP Antibody Major Customers
6.4.5 Latin America Market Trends and Opportunities
6.5 Middle East & Africa Market: Players, Segments, Downstream and Major Customers
6.5.1 Middle East & Africa Anti-GFP Antibody Revenue by Company (2021-2026)
6.5.2 Middle East & Africa Market Size by Type
6.5.2.1 Middle East & Africa Anti-GFP Antibody Market Size by Type (2021-2026)
6.5.2.2 Middle East & Africa Anti-GFP Antibody Market Share by Type (2021-2026)
6.5.3 Middle East & Africa Market Size by Application
6.5.3.1 Middle East & Africa Anti-GFP Antibody Market Size by Application (2021-2026)
6.5.3.2 Middle East & Africa Anti-GFP Antibody Market Share by Application (2021-2026)
6.5.4 Middle East & Africa Anti-GFP Antibody Major Customers
6.5.5 Middle East & Africa Market Trends and Opportunities
7 Key Player Profiles
7.1 FUJIFILM Wako Chemicals
7.1.1 FUJIFILM Wako Chemicals Company Details
7.1.2 FUJIFILM Wako Chemicals Business Overview
7.1.3 FUJIFILM Wako Chemicals Anti-GFP Antibody Introduction
7.1.4 FUJIFILM Wako Chemicals Revenue in Anti-GFP Antibody Business (2021-2026)
7.1.5 FUJIFILM Wako Chemicals Recent Development
7.2 ProSci
7.2.1 ProSci Company Details
7.2.2 ProSci Business Overview
7.2.3 ProSci Anti-GFP Antibody Introduction
7.2.4 ProSci Revenue in Anti-GFP Antibody Business (2021-2026)
7.2.5 ProSci Recent Development
7.3 GeneTex
7.3.1 GeneTex Company Details
7.3.2 GeneTex Business Overview
7.3.3 GeneTex Anti-GFP Antibody Introduction
7.3.4 GeneTex Revenue in Anti-GFP Antibody Business (2021-2026)
7.3.5 GeneTex Recent Development
7.4 Bioss
7.4.1 Bioss Company Details
7.4.2 Bioss Business Overview
7.4.3 Bioss Anti-GFP Antibody Introduction
7.4.4 Bioss Revenue in Anti-GFP Antibody Business (2021-2026)
7.4.5 Bioss Recent Development
7.5 Rockland Immunochemicals
7.5.1 Rockland Immunochemicals Company Details
7.5.2 Rockland Immunochemicals Business Overview
7.5.3 Rockland Immunochemicals Anti-GFP Antibody Introduction
7.5.4 Rockland Immunochemicals Revenue in Anti-GFP Antibody Business (2021-2026)
7.5.5 Rockland Immunochemicals Recent Development
7.6 Cell Signaling Technology
7.6.1 Cell Signaling Technology Company Details
7.6.2 Cell Signaling Technology Business Overview
7.6.3 Cell Signaling Technology Anti-GFP Antibody Introduction
7.6.4 Cell Signaling Technology Revenue in Anti-GFP Antibody Business (2021-2026)
7.6.5 Cell Signaling Technology Recent Development
7.7 Novus Biologicals
7.7.1 Novus Biologicals Company Details
7.7.2 Novus Biologicals Business Overview
7.7.3 Novus Biologicals Anti-GFP Antibody Introduction
7.7.4 Novus Biologicals Revenue in Anti-GFP Antibody Business (2021-2026)
7.7.5 Novus Biologicals Recent Development
7.8 Thermo Fisher Scientific
7.8.1 Thermo Fisher Scientific Company Details
7.8.2 Thermo Fisher Scientific Business Overview
7.8.3 Thermo Fisher Scientific Anti-GFP Antibody Introduction
7.8.4 Thermo Fisher Scientific Revenue in Anti-GFP Antibody Business (2021-2026)
7.8.5 Thermo Fisher Scientific Recent Development
7.9 Biorbyt
7.9.1 Biorbyt Company Details
7.9.2 Biorbyt Business Overview
7.9.3 Biorbyt Anti-GFP Antibody Introduction
7.9.4 Biorbyt Revenue in Anti-GFP Antibody Business (2021-2026)
7.9.5 Biorbyt Recent Development
7.10 R&D Systems
7.10.1 R&D Systems Company Details
7.10.2 R&D Systems Business Overview
7.10.3 R&D Systems Anti-GFP Antibody Introduction
7.10.4 R&D Systems Revenue in Anti-GFP Antibody Business (2021-2026)
7.10.5 R&D Systems Recent Development
7.11 BioLegend
7.11.1 BioLegend Company Details
7.11.2 BioLegend Business Overview
7.11.3 BioLegend Anti-GFP Antibody Introduction
7.11.4 BioLegend Revenue in Anti-GFP Antibody Business (2021-2026)
7.11.5 BioLegend Recent Development
7.12 OriGene Technologies
7.12.1 OriGene Technologies Company Details
7.12.2 OriGene Technologies Business Overview
7.12.3 OriGene Technologies Anti-GFP Antibody Introduction
7.12.4 OriGene Technologies Revenue in Anti-GFP Antibody Business (2021-2026)
7.12.5 OriGene Technologies Recent Development
7.13 ImmuQuest
7.13.1 ImmuQuest Company Details
7.13.2 ImmuQuest Business Overview
7.13.3 ImmuQuest Anti-GFP Antibody Introduction
7.13.4 ImmuQuest Revenue in Anti-GFP Antibody Business (2021-2026)
7.13.5 ImmuQuest Recent Development
7.14 Abbexa
7.14.1 Abbexa Company Details
7.14.2 Abbexa Business Overview
7.14.3 Abbexa Anti-GFP Antibody Introduction
7.14.4 Abbexa Revenue in Anti-GFP Antibody Business (2021-2026)
7.14.5 Abbexa Recent Development
7.15 EpiGentek
7.15.1 EpiGentek Company Details
7.15.2 EpiGentek Business Overview
7.15.3 EpiGentek Anti-GFP Antibody Introduction
7.15.4 EpiGentek Revenue in Anti-GFP Antibody Business (2021-2026)
7.15.5 EpiGentek Recent Development
7.16 Synaptic Systems
7.16.1 Synaptic Systems Company Details
7.16.2 Synaptic Systems Business Overview
7.16.3 Synaptic Systems Anti-GFP Antibody Introduction
7.16.4 Synaptic Systems Revenue in Anti-GFP Antibody Business (2021-2026)
7.16.5 Synaptic Systems Recent Development
7.17 Santa Cruz Biotechnology
7.17.1 Santa Cruz Biotechnology Company Details
7.17.2 Santa Cruz Biotechnology Business Overview
7.17.3 Santa Cruz Biotechnology Anti-GFP Antibody Introduction
7.17.4 Santa Cruz Biotechnology Revenue in Anti-GFP Antibody Business (2021-2026)
7.17.5 Santa Cruz Biotechnology Recent Development
7.18 Proteintech Group
7.18.1 Proteintech Group Company Details
7.18.2 Proteintech Group Business Overview
7.18.3 Proteintech Group Anti-GFP Antibody Introduction
7.18.4 Proteintech Group Revenue in Anti-GFP Antibody Business (2021-2026)
7.18.5 Proteintech Group Recent Development
7.19 IBL
7.19.1 IBL Company Details
7.19.2 IBL Business Overview
7.19.3 IBL Anti-GFP Antibody Introduction
7.19.4 IBL Revenue in Anti-GFP Antibody Business (2021-2026)
7.19.5 IBL Recent Development
7.20 LSBio
7.20.1 LSBio Company Details
7.20.2 LSBio Business Overview
7.20.3 LSBio Anti-GFP Antibody Introduction
7.20.4 LSBio Revenue in Anti-GFP Antibody Business (2021-2026)
7.20.5 LSBio Recent Development
7.21 Signalway Antibody
7.21.1 Signalway Antibody Company Details
7.21.2 Signalway Antibody Business Overview
7.21.3 Signalway Antibody Anti-GFP Antibody Introduction
7.21.4 Signalway Antibody Revenue in Anti-GFP Antibody Business (2021-2026)
7.21.5 Signalway Antibody Recent Development
7.22 Agrisera
7.22.1 Agrisera Company Details
7.22.2 Agrisera Business Overview
7.22.3 Agrisera Anti-GFP Antibody Introduction
7.22.4 Agrisera Revenue in Anti-GFP Antibody Business (2021-2026)
7.22.5 Agrisera Recent Development
7.23 Bio X Cell
7.23.1 Bio X Cell Company Details
7.23.2 Bio X Cell Business Overview
7.23.3 Bio X Cell Anti-GFP Antibody Introduction
7.23.4 Bio X Cell Revenue in Anti-GFP Antibody Business (2021-2026)
7.23.5 Bio X Cell Recent Development
7.24 StressMarq Biosciences
7.24.1 StressMarq Biosciences Company Details
7.24.2 StressMarq Biosciences Business Overview
7.24.3 StressMarq Biosciences Anti-GFP Antibody Introduction
7.24.4 StressMarq Biosciences Revenue in Anti-GFP Antibody Business (2021-2026)
7.24.5 StressMarq Biosciences Recent Development
7.25 RayBiotech
7.25.1 RayBiotech Company Details
7.25.2 RayBiotech Business Overview
7.25.3 RayBiotech Anti-GFP Antibody Introduction
7.25.4 RayBiotech Revenue in Anti-GFP Antibody Business (2021-2026)
7.25.5 RayBiotech Recent Development
7.26 Abnova
7.26.1 Abnova Company Details
7.26.2 Abnova Business Overview
7.26.3 Abnova Anti-GFP Antibody Introduction
7.26.4 Abnova Revenue in Anti-GFP Antibody Business (2021-2026)
7.26.5 Abnova Recent Development
8 Anti-GFP Antibody Market Dynamics
8.1 Anti-GFP Antibody Industry Trends
8.2 Anti-GFP Antibody Market Drivers
8.3 Anti-GFP Antibody Market Challenges
8.4 Anti-GFP Antibody Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Anti-GFP Antibody Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Global Anti-GFP Antibody Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 3. Global Market Anti-GFP Antibody Market Size (US$ Million) by Region:2021 vs 2025 vs 2032
Table 4. Global Anti-GFP Antibody Revenue (US$ Million) Market Share by Region (2021-2026)
Table 5. Global Anti-GFP Antibody Revenue Share by Region (2021-2026)
Table 6. Global Anti-GFP Antibody Revenue (US$ Million) Forecast by Region (2027-2032)
Table 7. Global Anti-GFP Antibody Revenue Share Forecast by Region (2027-2032)
Table 8. Global Anti-GFP Antibody Market Size by Type (2021-2026) & (US$ Million)
Table 9. Global Anti-GFP Antibody Market Share by Revenue, by Type (2021-2026)
Table 10. Global Anti-GFP Antibody Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 11. Global Anti-GFP Antibody Market Share by Revenue, by Type (2027-2032)
Table 12. Representative Players of Each Type
Table 13. Global Anti-GFP Antibody Market Size by Application (2021-2026) & (US$ Million)
Table 14. Global Anti-GFP Antibody Market Share by Revenue, by Application (2021-2026)
Table 15. Global Anti-GFP Antibody Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 16. Global Anti-GFP Antibody Market Share by Revenue, by Application (2027-2032)
Table 17. New Sources of Growth in Anti-GFP Antibody Applications
Table 18. Global Anti-GFP Antibody Revenue by Players (2021-2026) & (US$ Million)
Table 19. Global Anti-GFP Antibody Market Share by Players (2021-2026)
Table 20. Global Top Anti-GFP Antibody Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-GFP Antibody as of 2025)
Table 21. Ranking of Global Top Anti-GFP Antibody Companies by Revenue (US$ Million) in 2025
Table 22. Global 5 Largest Players Market Share by Anti-GFP Antibody Revenue (CR5 and HHI) & (2021-2026)
Table 23. Global Key Players of Anti-GFP Antibody, Headquarters and Area Served
Table 24. Global Key Players of Anti-GFP Antibody, Product and Application
Table 25. Global Key Players of Anti-GFP Antibody, Date of Entry into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Anti-GFP Antibody Revenue by Company (2021-2026) & (US$ Million)
Table 28. North America Anti-GFP Antibody Market Share by Revenue, by Company (2021-2026)
Table 29. North America Anti-GFP Antibody Market Size by Type (2021-2026) & (US$ Million)
Table 30. North America Anti-GFP Antibody Market Size by Application (2021-2026) & (US$ Million)
Table 31. Europe Anti-GFP Antibody Revenue by Company (2021-2026) & (US$ Million)
Table 32. Europe Anti-GFP Antibody Market Share by Revenue, by Company (2021-2026)
Table 33. Europe Anti-GFP Antibody Market Size by Type (2021-2026) & (US$ Million)
Table 34. Europe Anti-GFP Antibody Market Size by Application (2021-2026) & (US$ Million)
Table 35. Asia-Pacific Anti-GFP Antibody Revenue by Company (2021-2026) & (US$ Million)
Table 36. Asia-Pacific Anti-GFP Antibody Market Share by Revenue, by Company (2021-2026)
Table 37. Asia-Pacific Anti-GFP Antibody Market Size by Type (2021-2026) & (US$ Million)
Table 38. Asia-Pacific Anti-GFP Antibody Market Size by Application (2021-2026) & (US$ Million)
Table 39. Latin America Anti-GFP Antibody Revenue by Company (2021-2026) & (US$ Million)
Table 40. Latin America Anti-GFP Antibody Market Share by Revenue, by Company (2021-2026)
Table 41. Latin America Anti-GFP Antibody Market Size by Type (2021-2026) & (US$ Million)
Table 42. Latin America Anti-GFP Antibody Market Size by Application (2021-2026) & (US$ Million)
Table 43. Middle East & Africa Anti-GFP Antibody Revenue by Company (2021-2026) & (US$ Million)
Table 44. Middle East & Africa Anti-GFP Antibody Market Share by Revenue, by Company (2021-2026)
Table 45. Middle East & Africa Anti-GFP Antibody Market Size by Type (2021-2026) & (US$ Million)
Table 46. Middle East & Africa Anti-GFP Antibody Market Size by Application (2021-2026) & (US$ Million)
Table 47. FUJIFILM Wako Chemicals Company Details
Table 48. FUJIFILM Wako Chemicals Business Overview
Table 49. FUJIFILM Wako Chemicals Anti-GFP Antibody Product
Table 50. FUJIFILM Wako Chemicals Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 51. FUJIFILM Wako Chemicals Recent Development
Table 52. ProSci Company Details
Table 53. ProSci Business Overview
Table 54. ProSci Anti-GFP Antibody Product
Table 55. ProSci Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 56. ProSci Recent Development
Table 57. GeneTex Company Details
Table 58. GeneTex Business Overview
Table 59. GeneTex Anti-GFP Antibody Product
Table 60. GeneTex Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 61. GeneTex Recent Development
Table 62. Bioss Company Details
Table 63. Bioss Business Overview
Table 64. Bioss Anti-GFP Antibody Product
Table 65. Bioss Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 66. Bioss Recent Development
Table 67. Rockland Immunochemicals Company Details
Table 68. Rockland Immunochemicals Business Overview
Table 69. Rockland Immunochemicals Anti-GFP Antibody Product
Table 70. Rockland Immunochemicals Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 71. Rockland Immunochemicals Recent Development
Table 72. Cell Signaling Technology Company Details
Table 73. Cell Signaling Technology Business Overview
Table 74. Cell Signaling Technology Anti-GFP Antibody Product
Table 75. Cell Signaling Technology Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 76. Cell Signaling Technology Recent Development
Table 77. Novus Biologicals Company Details
Table 78. Novus Biologicals Business Overview
Table 79. Novus Biologicals Anti-GFP Antibody Product
Table 80. Novus Biologicals Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 81. Novus Biologicals Recent Development
Table 82. Thermo Fisher Scientific Company Details
Table 83. Thermo Fisher Scientific Business Overview
Table 84. Thermo Fisher Scientific Anti-GFP Antibody Product
Table 85. Thermo Fisher Scientific Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 86. Thermo Fisher Scientific Recent Development
Table 87. Biorbyt Company Details
Table 88. Biorbyt Business Overview
Table 89. Biorbyt Anti-GFP Antibody Product
Table 90. Biorbyt Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 91. Biorbyt Recent Development
Table 92. R&D Systems Company Details
Table 93. R&D Systems Business Overview
Table 94. R&D Systems Anti-GFP Antibody Product
Table 95. R&D Systems Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 96. R&D Systems Recent Development
Table 97. BioLegend Company Details
Table 98. BioLegend Business Overview
Table 99. BioLegend Anti-GFP Antibody Product
Table 100. BioLegend Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 101. BioLegend Recent Development
Table 102. OriGene Technologies Company Details
Table 103. OriGene Technologies Business Overview
Table 104. OriGene Technologies Anti-GFP Antibody Product
Table 105. OriGene Technologies Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 106. OriGene Technologies Recent Development
Table 107. ImmuQuest Company Details
Table 108. ImmuQuest Business Overview
Table 109. ImmuQuest Anti-GFP Antibody Product
Table 110. ImmuQuest Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 111. ImmuQuest Recent Development
Table 112. Abbexa Company Details
Table 113. Abbexa Business Overview
Table 114. Abbexa Anti-GFP Antibody Product
Table 115. Abbexa Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 116. Abbexa Recent Development
Table 117. EpiGentek Company Details
Table 118. EpiGentek Business Overview
Table 119. EpiGentek Anti-GFP Antibody Product
Table 120. EpiGentek Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 121. EpiGentek Recent Development
Table 122. Synaptic Systems Company Details
Table 123. Synaptic Systems Business Overview
Table 124. Synaptic Systems Anti-GFP Antibody Product
Table 125. Synaptic Systems Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 126. Synaptic Systems Recent Development
Table 127. Santa Cruz Biotechnology Company Details
Table 128. Santa Cruz Biotechnology Business Overview
Table 129. Santa Cruz Biotechnology Anti-GFP Antibody Product
Table 130. Santa Cruz Biotechnology Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 131. Santa Cruz Biotechnology Recent Development
Table 132. Proteintech Group Company Details
Table 133. Proteintech Group Business Overview
Table 134. Proteintech Group Anti-GFP Antibody Product
Table 135. Proteintech Group Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 136. Proteintech Group Recent Development
Table 137. IBL Company Details
Table 138. IBL Business Overview
Table 139. IBL Anti-GFP Antibody Product
Table 140. IBL Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 141. IBL Recent Development
Table 142. LSBio Company Details
Table 143. LSBio Business Overview
Table 144. LSBio Anti-GFP Antibody Product
Table 145. LSBio Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 146. LSBio Recent Development
Table 147. Signalway Antibody Company Details
Table 148. Signalway Antibody Business Overview
Table 149. Signalway Antibody Anti-GFP Antibody Product
Table 150. Signalway Antibody Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 151. Signalway Antibody Recent Development
Table 152. Agrisera Company Details
Table 153. Agrisera Business Overview
Table 154. Agrisera Anti-GFP Antibody Product
Table 155. Agrisera Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 156. Agrisera Recent Development
Table 157. Bio X Cell Company Details
Table 158. Bio X Cell Business Overview
Table 159. Bio X Cell Anti-GFP Antibody Product
Table 160. Bio X Cell Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 161. Bio X Cell Recent Development
Table 162. StressMarq Biosciences Company Details
Table 163. StressMarq Biosciences Business Overview
Table 164. StressMarq Biosciences Anti-GFP Antibody Product
Table 165. StressMarq Biosciences Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 166. StressMarq Biosciences Recent Development
Table 167. RayBiotech Company Details
Table 168. RayBiotech Business Overview
Table 169. RayBiotech Anti-GFP Antibody Product
Table 170. RayBiotech Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 171. RayBiotech Recent Development
Table 172. Abnova Company Details
Table 173. Abnova Business Overview
Table 174. Abnova Anti-GFP Antibody Product
Table 175. Abnova Revenue in Anti-GFP Antibody Business (2021-2026) & (US$ Million)
Table 176. Abnova Recent Development
Table 177. Anti-GFP Antibody Market Trends
Table 178. Anti-GFP Antibody Market Drivers
Table 179. Anti-GFP Antibody Market Challenges
Table 180. Anti-GFP Antibody Market Restraints
Table 181. Research Programs/Design for This Report
Table 182. Key Data Information from Secondary Sources
Table 183. Key Data Information from Primary Sources


List of Figures
Figure 1. Anti-GFP Antibody Product Picture
Figure 2. Global Anti-GFP Antibody Market Share by Type: 2025 vs 2032
Figure 3. Monoclonal Antibody Features
Figure 4. Polyclonal Antibody Features
Figure 5. Global Anti-GFP Antibody Market Share by Application: 2025 vs 2032
Figure 6. Biotechnology
Figure 7. Medical
Figure 8. University
Figure 9. Others
Figure 10. Anti-GFP Antibody Report Years Considered
Figure 11. Global Anti-GFP Antibody Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 12. Global Anti-GFP Antibody Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global Anti-GFP Antibody Market Share by Revenue, by Region: 2021 vs 2025
Figure 14. North America Anti-GFP Antibody Revenue (US$ Million) Growth Rate (2021-2032)
Figure 15. Europe Anti-GFP Antibody Revenue (US$ Million) Growth Rate (2021-2032)
Figure 16. Asia-Pacific Anti-GFP Antibody Revenue (US$ Million) Growth Rate (2021-2032)
Figure 17. Latin America Anti-GFP Antibody Revenue (US$ Million) Growth Rate (2021-2032)
Figure 18. Middle East & Africa Anti-GFP Antibody Revenue (US$ Million) Growth Rate (2021-2032)
Figure 19. Global Anti-GFP Antibody Market Share by Players in 2025
Figure 20. Global Top Anti-GFP Antibody Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-GFP Antibody as of 2025)
Figure 21. The Top 10 and 5 Players Market Share by Anti-GFP Antibody Revenue in 2025
Figure 22. North America Anti-GFP Antibody Market Share by Type (2021-2026)
Figure 23. North America Anti-GFP Antibody Market Share by Application (2021-2026)
Figure 24. Europe Anti-GFP Antibody Market Share by Type (2021-2026)
Figure 25. Europe Anti-GFP Antibody Market Share by Application (2021-2026)
Figure 26. Asia-Pacific Anti-GFP Antibody Market Share by Type (2021-2026)
Figure 27. Asia-Pacific Anti-GFP Antibody Market Share by Application (2021-2026)
Figure 28. Latin America Anti-GFP Antibody Market Share by Type (2021-2026)
Figure 29. Latin America Anti-GFP Antibody Market Share by Application (2021-2026)
Figure 30. Middle East & Africa Anti-GFP Antibody Market Share by Type (2021-2026)
Figure 31. Middle East & Africa Anti-GFP Antibody Market Share by Application (2021-2026)
Figure 32. FUJIFILM Wako Chemicals Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 33. ProSci Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 34. GeneTex Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 35. Bioss Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 36. Rockland Immunochemicals Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 37. Cell Signaling Technology Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 38. Novus Biologicals Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 39. Thermo Fisher Scientific Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 40. Biorbyt Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 41. R&D Systems Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 42. BioLegend Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 43. OriGene Technologies Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 44. ImmuQuest Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 45. Abbexa Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 46. EpiGentek Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 47. Synaptic Systems Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 48. Santa Cruz Biotechnology Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 49. Proteintech Group Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 50. IBL Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 51. LSBio Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 52. Signalway Antibody Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 53. Agrisera Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 54. Bio X Cell Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 55. StressMarq Biosciences Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 56. RayBiotech Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 57. Abnova Revenue Growth Rate in Anti-GFP Antibody Business (2021-2026)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed